Loading...
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Morgan, Robert David Clamp, Andrew R Evans, D Edmondson, R Jayson, Gordon C
Morgan, Robert David
Clamp, Andrew R
Evans, D
Edmondson, R
Jayson, Gordon C
Citations
Altmetric:
Abstract
Poly(ADP-ribose) polymerase inhibitors (PARPi) have changed the management of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi was based on the concept of synthetic lethality, in which a cell can survive a deficiency of one gene/gene product, but may die if there is a deficiency in a combination of genes/gene products. In women with BRCA1/2 deficiency within their ovarian cancer tissue, inhibition of PARP imposes an intolerable burden of DNA damage repair deficiency and may induce cell death.
Description
Date
2018-04
Publisher
Collections
Files
Keywords
Type
Article
Citation
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. 2018, 81(4): 647-658 Cancer Chemother Pharmacol